Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nymox Corporation
Age
45–85
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
T1c prostate cancer
Gleason score ≤ 6 with no Gleason pattern of 4 or 5.
Life expectancy ≥ 5 years.
Single positive prostate biopsy core with ≤ 50% cancer
PSA ≤ 10 ng/mL
You may not be if
Previous active treatment (such as surgery, brachytherapy, radiotherapy) for prostate cancer.
Evidence of metastatic disease or previous positive bone scan.
Previous hormonal therapy for prostate cancer.
Use of certain concomitant medications, including 5 alpha reductase inhibitors (e.g. finasteride, dutasteride), androgen receptor blockers (e.g. flutamide, bicalutamide), immunosuppressants(such as Imuran™, Enbrel™, Remicade™, Humira™, etc.), anticoagulants(such as Coumadin™ or heparin), or chemotherapeutics.
Previous surgical or invasive prostate treatments such as TURP, TUMT, TUNA, laser or any other minimally invasive treatment within the past 12 months.
Pelvic irradiation.
Urinary tract infection more than once in the past 12 months.
Acute or chronic prostatitis in the past 12 months.
Clinically significant renal or hepatic impairment.
Bleeding disorder.
Poorly controlled diabetes type 1 or type 2.
Urinary retention in the previous 12 months.
Self-catheterization for urinary retention.
Post-void residual urine volume \> 200 mL.
Prior significant rectal surgery or any rectal condition with rectal stenosis or fistula.
History of alcohol or substance abuse or dependence within the past 2 years.
